All > Giant Cell Arteritis > California

Secukinumab 300 mg for Giant Cell Arteritis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Giant Cell ArteritisSecukinumab 300 mg - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it's effective and safe for people with a disease that causes inflammation in the arteries.

Eligible Conditions
  • Giant Cell Arteritis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
PREG 300/500 mg
1
Probenecid 500 MG
1
AAV8-hCocH

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 52 weeks

12 weeks
Number of participants with clinical failure
52 Weeks
Gas Chromatography
52 weeks
Change in EQ-5D score
Change in FACIT-Fatigue Score
Change in GlucocorticoidToxicity Index (GTI)
Change in SF-36 score (PCS)
Cumulative GC dose
Number of participants with sustained remission
Proportion of participants with sustained remission
Safety and tolerability of secukinumab
Time to clinical failure

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
PREG 300/500 mg
1
Probenecid 500 MG
1
AAV8-hCocH

Side Effects for

Secukinumab 300 mg
20%Nasopharyngitis
13%Upper respiratory tract infection
11%Arthralgia
7%Bronchitis
7%Diarrhoea
2%Rib fracture
2%Upper limb fracture
2%Aortic stenosis
2%Dizziness
2%Muscular weakness
2%Abdominal pain
2%Cough
This histogram enumerates side effects from a completed 2018 Phase 4 trial (NCT02690701) in the Secukinumab 300 mg ARM group. Side effects include: Nasopharyngitis with 20%, Upper respiratory tract infection with 13%, Arthralgia with 11%, Bronchitis with 7%, Diarrhoea with 7%.

Trial Design

3 Treatment Groups

Secukinumab 150 mg
1 of 3
Secukinumab 300 mg
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

349 Total Participants · 3 Treatment Groups

Primary Treatment: Secukinumab 300 mg · Has Placebo Group · Phase 3

Secukinumab 150 mg
Biological
Experimental Group · 1 Intervention: Secukinumab 150 mg · Intervention Types: Biological
Secukinumab 300 mg
Biological
Experimental Group · 1 Intervention: Secukinumab 300 mg · Intervention Types: Biological
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Secukinumab 150 mg
2016
Completed Phase 4
~260
Secukinumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 52 weeks

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,717 Previous Clinical Trials
3,524,506 Total Patients Enrolled
3 Trials studying Giant Cell Arteritis
214 Patients Enrolled for Giant Cell Arteritis

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patient must be able to understand and comply with the requirements of the study.
You have symptoms of polymyalgia rheumatica (PMR) and/or symptoms of limb ischemia (claudication).
You have signs or symptoms attributed to active GCA and not related to prior damage.
You have a diagnosis of GCA within 6 weeks of a BSL visit.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top